Ocugen Inc OCGN shares are trading lower by 5.86% to $2.73 during Tuesday's pre-market session after the company announced that it was informed by the FDA that the agency placed its Phase 2/3 immuno-bridging and broadening study for COVAXIN, OCU-002, on clinical hold.
Ocugen says this is a result of the company’s decision to voluntarily implement a temporary pause in dosing participants of OCU-002 while it evaluates statements made by the World Health Organization following their inspection of Bharat Biotech International Limited’s (BBIL) manufacturing facility. Ocugen will work with the FDA to address any questions.
Ocugen is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19.
Ocugen has a 52-week high of $17.65 and a 52-week low of $2.16.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.